Galderma is the leading company solely dedicated to the body’s largest organ: the skin. We are strategically positioned in resilient, highly attractive and consumer-focused sub-segments of Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.
Our unique Integrated Dermatology Strategy capitalizes on our distinctive strengths and competitive advantage.
Through trust-based partnerships with healthcare professionals, we meet consumer and patient needs with superior, lasting outcomes. Together, we are shaping the future of dermatology.
KEY FACTS ABOUT GALDERMA
4.082 B USD
2023 net sales
4
manufacturing sites
300+
million units produced a year
6,500+
employees operate from 50 sites in 40 countries, with our headquarters in Switzerland
770+
clinical trials funded across 30+ countries since 2019
160+
major regulatory approvals since 2019
11,000+
training events via our Global Aesthetic Injector Network (GAIN) program in 2023
130,000+
Training participants per year* engaged via our Global Aesthetic Injector Network (GAIN) program in 2023
* Single training contact – one healthcare professional can attend more than one training
Find out about our leadership team
A timeline of our history
1981
Foundation of Galderma as a joint venture between L’Oréal and Nestlé
Following the invention of the first Cetaphil formulation in 1947
1984
Galderma discovers Adapalene
1986
First commercial operations
1995
Launch of Differin for acne treatment
2000
Opening of our production site in Baie d’Urfé, Canada
2001
Licensing agreement for Metvix (Skin cancer)
2004
Opening of our production site in Hortolândia, Brazil
2007
Launch of Differin 0.3%
2008
Launch of Epiduo
2009
Launch of Azzalure and Restylane Injector
